Background Energy metabolism reprogramming of cancer cells with the abnormal glycolytic capacity represents a novel direction of tumor therapy. Nevertheless, there is a lack of evidence linking genetic variations in glycolysis‐related genes to the risk and clinical progression of lung cancer (LC). This study is aimed at clarifying the genetic effect of glycolytic pathway‐related genes on the occurrence and development of LC. Methods In this two‐stage case‐control study, we enrolled 300 LC patients and 600 healthy controls, as well as 1248 case‐control pairs from several hospitals in Guangzhou, to evaluate the association between the genetic variations of glycolysis‐related genes ( GLUT1 rs1385129G>A, GLUT11 rs6003939A>C, GLUT12 rs1484180G>A and ENO2 rs11064467C>T) and the risk of LC. Follow‐up data and the TCGA database were used to evaluate the relationship between GLUT1 rs1385129G>A and GLUT1 expression with the clinical progression of LC. Results Only GLUT1 rs1385129G>A was found to be associated with increased risk of LC in this two‐stage case‐control study ( p A genotypes showed that they were positively correlated with the number of A alleles ( p A may increase the risk of LC and contribute to a poor prognosis by upregulating GLUT1 expression.
Li et al. (Thu,) studied this question.